Evidence map›Paper›PMID 40933999›Full record

ArticleFrontiers in immunology2025

A novel and rapid method to purify the human complement opsonin C3b from human plasma.

Jannik Sichau, Christoph Q Schmidt

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jannik SichauInstitute of Experimental and Clinical Pharmacology, Toxicology and Pharmacology of Natural Products, University of Ulm Medical Centre, Ulm, Germany.
Christoph Q SchmidtInstitute of Experimental and Clinical Pharmacology, Toxicology and Pharmacology of Natural Products, University of Ulm Medical Centre, Ulm, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Complement opsonin C3b is at the center of the complement cascade. All complement initiation pathways converge when convertases activate C3, converting it into the anaphylatoxin C3a and the opsonin C3b, which can attach to surfaces via its freshly exposed thioester moiety. C3b has several important functions and remains a focus of basic and translational research. C3b and its proteolytically processed derivatives iC3b and C3dg are important opsonins for different complement receptors on various immune cells. C3b is the initiation nucleus for the formation of the alternative pathway C3 convertase and C3b clusters act as gatekeepers for the activation of C5, which initiates the terminal pathway. High densities of surface-deposited C3b alter the substrate specificity of complement convertases from C3 to C5 activation. It remains unknown how C3b achieves the "C5 priming" necessary for this process. Further exploration of the functions of C3b is laborious, as it generally requires the purification of C3 from plasma/serum, subsequent conversion to C3b, and further purification. Therefore, we developed a rapid (three days) and efficient method that purifies C3b directly from blood sources, requiring fewer steps and reagents than previously published protocols. This method utilizes the newly exposed sulfhydryl group, which becomes accessible by converting C3 to C3b. The C3b purified by this method exhibits high purity and very high activity, as demonstrated by affinity measurements for several known C3b ligands, the formation and dissociation of the alternative pathway convertase, and the capacity to be regulated by FI.

Indexed as

Complement C3bOpsonin ProteinsComplement ActivationHumansComplement C3bOpsonin ProteinsC3bcomplement - immunological termsfactor Iopsoninspurification method

Identifiers

PMID40933999
PMCPMC12417186

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.